Pacific Century Group

22nd Century Group (Nasdaq: XXII) Appoints R. Hugh Kinsman as CFO

Retrieved on: 
Thursday, June 16, 2022
Solution, CPAS, FDA, Tobacco, Smoking, MBA, Asher, Pennsylvania State University, Genetic engineering, XXII, Company, MRTP, Plant, Forward-looking statement, Disease, Certified Public Accountant, Health, CFO, GE Capital, Nasdaq, Death, Cornell University, Century, Pacific Century Group, BDO, Nicotine, RNC, GVB, Media, GLOBE

CFO of GVB Biopharma to Expand Role, Become CFO of 22nd Century Group

Key Points: 
  • CFO of GVB Biopharma to Expand Role, Become CFO of 22nd Century Group
    BUFFALO, N.Y., June 16, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company), dedicated to improving human health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technology, today announced the appointment of R. Hugh Kinsman as Chief Financial Officer.
  • Kinsman is currently CFO of GVB Biopharma, which 22nd Century acquired effective May 13, 2022.
  • The integration of GVB Biopharma is proceeding very well, and we are excited to build on Hughs success at GVB by elevating his financial leadership role to 22nd Century as a whole, said James A. Mish, chief executive officer of 22nd Century Group.
  • 22nd Century Group, Inc. (Nasdaq: XXII ) is a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science.

22nd Century Group (Nasdaq: XXII) to Participate in LD Micro, Roth Capital Investor Meetings

Retrieved on: 
Friday, May 27, 2022
Death, Company, Disease, Plant, RNC, Nasdaq, XXII, Genetic engineering, Solution, Health, Pacific Century Group, FDA, Media, Century, MRTP, Smoking, Nicotine, Forward-looking statement, Tobacco

Institutional investors participating in the conference can request a meeting with management through their institutional representative, or by contacting 22nd Century Groups investor relations team via [email protected] .

Key Points: 
  • Institutional investors participating in the conference can request a meeting with management through their institutional representative, or by contacting 22nd Century Groups investor relations team via [email protected] .
  • The Company received the first and only FDA MRTP authorization of a combustible cigarette in December 2021, now in a pilot marketing program in the United States.
  • Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements.
  • Actual results might differ materially from those explicit or implicit in forward-looking statements.

22nd Century Group (Nasdaq: XXII) Announces John J. Miller Joins Its Tobacco Business

Retrieved on: 
Monday, May 23, 2022
CEO, MBA, UNLV, Company, History, Death, Disease, Plant, RNC, Business administration, Region, Strategic planning, Nasdaq, XXII, U.S. Smokeless Tobacco Company, Smoke, Genetic engineering, Science, Solution, Health, Pepperdine University, Pacific Century Group, Acosta Sales & Marketing, FDA, Century, MRTP, Tobacco, Partnership, Smokeless tobacco, Smoking, Nicotine, Forward-looking statement, Growth, GLOBE, Management, Altria

BUFFALO, N.Y., May 23, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through modern plant science, today announced John J. Miller will direct the growth and achieve the full potential of the Company’s reduced nicotine tobacco business. Mr. Miller has more than 35 years of experience in the tobacco and consumer packaged goods industries. He has demonstrated his ability to develop high performance work environments that have achieved a very strong track record of success and superior commercial results. Mr. Miller will work directly with Jim Mish, Chief Executive Officer and also with Michael Zercher, Chief Operating Officer of 22nd Century Group.

Key Points: 
  • Mr. Miller has more than 35 years of experience in the tobacco and consumer packaged goods industries.
  • Mr. Miller will work directly with Jim Mish, Chief Executive Officer and also with Michael Zercher, Chief Operating Officer of 22nd Century Group.
  • John Miller said, I am extremely impressed with the team of outstanding professionals at 22nd Century Group and their commitment to product innovation.
  • 22nd Century Group, Inc. (Nasdaq: XXII ) is a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science.

22nd Century Group (Nasdaq: XXII) Begins Integration of GVB Biopharma, Creating a Complete, Robust Hemp/Cannabis Platform

Retrieved on: 
Wednesday, May 18, 2022
GVB, Death, NSF, Company, Disease, Plant, CBD, RNC, EBITDA, Nasdaq, XXII, Genetic engineering, Science, CDMO, Solution, Health, Biomass, Cannabinoid, CGMP, Investor, Pacific Century Group, FDA, Efficiency, Century, MRTP, Genetics, Industry, UK, CBDA, Smoking, Nicotine, Forward-looking statement, Tobacco, Tablet, Acquisition, Growth, GLOBE, Fine chemical, Agriculture, Central Oregon

James A. Mish, chief executive officer of 22nd Century Group, stated: We are excited to welcome the GVB team into the 22nd Century family.

Key Points: 
  • James A. Mish, chief executive officer of 22nd Century Group, stated: We are excited to welcome the GVB team into the 22nd Century family.
  • GVB is widely regarded as a best-in-class operator with an estimated 15% share of the hemp derived active ingredients market.
  • The combination of GVB into 22nd Century also deepens its global footprint in geographic markets targeted for growth, including opportunities to accelerate 22nd Centurys strategy in key international markets.
  • 22nd Century intends to capitalize on emerging trends in the expanding hemp/cannabis industry to generate significant increases in revenue.

22nd Century Group (Nasdaq: XXII) Acquires GVB Biopharma, a Leading Hemp/Cannabis Company

Retrieved on: 
Friday, May 13, 2022
GVB, Death, Company, Disease, CBD, Plant, RNC, EBITDA, GMP, Nasdaq, XXII, Genetic engineering, Science, CDMO, Solution, Health, Breeding, Marketing, Pacific Century Group, Research, United Kingdom, FDA, Efficiency, Keygen, MRTP, Industry, Genetics, Century, Partnership, Intellectual property, Smoking, Nicotine, Dorsey & Whitney, Forward-looking statement, Tobacco, Acquisition, GLOBE, Fine chemical, Drug, Agriculture, Central Oregon

The combination with 22nd Century establishes a global one-of-a-kind asset to serve the rapidly growing hemp/cannabis ingredient market.

Key Points: 
  • The combination with 22nd Century establishes a global one-of-a-kind asset to serve the rapidly growing hemp/cannabis ingredient market.
  • James A. Mish, chief executive officer of 22nd Century Group, stated: GVB represents a transformational acquisition for 22nd Century that will enable us to rapidly grow our hemp/cannabis franchise.
  • GVB is one of the largest CBD suppliers globally, possessing innovative, vertically integrated cannabinoid product manufacturing technologies driving industry leading scale and cost efficiency.
  • We are excited to combine with 22nd Century group, pairing our production and manufacturing capabilities together with the best hemp/cannabis plant science in the world, said Phillip Swindells, Chief Executive Officer at GVB.

22nd Century Group (Nasdaq: XXII) Expects VLN® Menthol King Reduced Nicotine Cigarettes To Be Exempted From FDA’s Proposed Ban on Menthol Cigarettes

Retrieved on: 
Friday, April 29, 2022
Smoke, Solution, Adult, XXII, Pacific Century Group, Nicotine, Plant, Genetic engineering, Time, Public health, Menthol, Nasdaq, MRTP, Smokeless tobacco, FDA, GLOBE, Death, VLN, Regulatory science, Forward-looking statement, RNC, Century, Company, Science, Health equity, Smoking, Tobacco, Health, Smoker, Disease, Media

Our VLN Menthol King reduced nicotine cigarettes are an unmatched tool for helping adult menthol smokers find an off-ramp from nicotine addiction.

Key Points: 
  • Our VLN Menthol King reduced nicotine cigarettes are an unmatched tool for helping adult menthol smokers find an off-ramp from nicotine addiction.
  • 22nd Centurys VLN King and VLN Menthol King are the cornerstone of FDAs public health mission for tobacco, continued Mish.
  • The FDA authorized 22nd Centurys MRTP for VLN reduced nicotine content cigarette products on December 23, 2021.
  • VLN King and VLN Menthol King are the only FDA authorized reduced nicotine content combustible cigarettes in the U.S. tobacco products market, estimated at approximately $80 billion in size.

22nd Century Group (Nasdaq: XXII) Issues Annual Letter to Shareholders

Retrieved on: 
Thursday, April 28, 2022
Smoke, Solution, Adult, XXII, Keygen, Pacific Century Group, Nicotine, Genetic engineering, Biomass, Plant, Time, Breeding, Tobacco, Smokeless tobacco, Nasdaq, MRTP, Letter, FDA, The Non-GMO Project, IP, Gene editing, GLOBE, Death, Beer, Food, Forward-looking statement, RNC, Disease, Century, Company, Intellectual property, Annual report, Exercise, Commissioner of Food and Drugs, Smoking, Research, Genetics, Menthol, Industry, Regulation of tobacco by the U.S. Food and Drug Administration, Health, Smoker, Media

---

Key Points: 
  • BUFFALO, N.Y., April 28, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco, and improving health and wellness through modern plant science, today announced that the Company has issued its annual letter to shareholders as part of 22nd Centurys 2021 Annual Report.
  • In addition, 22nd Century Group will be hosting its annual meeting of stockholders on Thursday, June 16, 2022, at 10 a.m.
  • In closing, I thank you for your continued support of 22nd Century and its initiatives and look forward to our continued progress in these exciting markets.
  • 22nd Century Group, Inc. (Nasdaq: XXII ) is a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science.

22nd Century Group (Nasdaq: XXII) to Participate in A.G.P./Alliance Global Partner’s Virtual Spring Consumer Cannabis Conference

Retrieved on: 
Wednesday, April 27, 2022
Genetic engineering, RNC, Media, Plant, Pacific Century Group, Century, GLOBE, Death, Tobacco, Conference, XXII, MRTP, Nasdaq, Company, Smoking, Solution, Forward-looking statement, Nicotine, FDA, Disease, Health

Institutional investors participating in the conference can request a meeting with management through their Alliance Global Partners representative, or by contacting 22nd Century Groups investor relations team via [email protected] .

Key Points: 
  • Institutional investors participating in the conference can request a meeting with management through their Alliance Global Partners representative, or by contacting 22nd Century Groups investor relations team via [email protected] .
  • 22nd Century Group, Inc. (Nasdaq: XXII ) is a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science.
  • The Company received the first and only FDA MRTP authorization of a combustible cigarette in December 2021.
  • Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements.

22nd Century Group (Nasdaq: XXII) to Announce First Quarter 2022 Results on May 5, 2022

Retrieved on: 
Thursday, April 14, 2022
Genetic engineering, Investor relations, RNC, Media, Plant, Software, Pacific Century Group, Century, GLOBE, Death, Q&A, Tobacco, XXII, MRTP, Company, Nasdaq, Smoking, Solution, Webcast, Forward-looking statement, Nicotine, R. J. Reynolds Tobacco Company, FDA, Disease, Health, Public relations

22nd Century will report the Companys first quarter 2022 results in a press release at 6:00 AM ET the same day.

Key Points: 
  • 22nd Century will report the Companys first quarter 2022 results in a press release at 6:00 AM ET the same day.
  • Following prepared remarks by management and slide presentation, the Company will host a Q&A session, during which management will accept questions from interested analysts.
  • 22nd Century Group, Inc. (Nasdaq: XXII ) is a leading agricultural biotechnology company focused on tobacco harm reduction, reduced nicotine tobacco and improving health and wellness through plant science.
  • Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements.

First Cigarette That "Helps You Smoke Less" Launches National Pilot in Chicagoland

Retrieved on: 
Wednesday, April 13, 2022
Center, Circle K, Smoke, NIDA, Genetic engineering, Mayo Clinic, RNC, Marketing, Plant, Population, CDC, Centers for Disease Control and Prevention, Chicago Medical Society, Adult, National Cancer Institute, Regulation of tobacco by the U.S. Food and Drug Administration, Research, Ageing, National Institute on Drug Abuse, MD, Academy of Technological Sciences of Ukraine, Taste, Food, Pacific Century Group, Century, Smokeless tobacco, GLOBE, Death, National, Patient, Directory, Tobacco, Burns, XXII, MRTP, Nasdaq, Company, Smoker, Food and Drug Administration, Language, Smoking, Solution, Forward-looking statement, National Institute, Nicotine, Smell, VLN, FDA, Disease, NCI, Health, Johns Hopkins University, University, Chicago metropolitan area

CHICAGO, April 13, 2022 (GLOBE NEWSWIRE) -- The first and only combustible tobacco cigarette containing minimal to non-addictive levels of nicotine and authorized by the U.S. Food and Drug Administration (FDA) to help adult smokers smoke less is now available through a national pilot exclusively in select Chicagoland Circle K stores.

Key Points: 
  • Additionally, the FDA requires each package of VLN to prominently display the evidence based claim Helps you smoke less.
  • If the FDA says this reduced nicotine cigarette will help people smoke less, then as doctors its something we need to consider for patients.
  • When choosing Chicagoland for the pilot, 22nd Century noted smokers are found within every segment of the population, many of whom are looking for alternatives.
  • The CDC estimates 15.5% of Illinois adults aged 18 years or older smoke cigarettes, higher than the national average of 12.5%, according to 2018 state and 2020 national statistics.